Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arno Therapeutics has entered into a worldwide licensing agreement with Invivis Pharmaceuticals to develop onapristone, an anti-progestin hormone blocker having considerable anti-tumor activity in breast cancer.
Subscribe to our email newsletter
As per the terms of the agreement, Arno will pay certain research, clinical and regulatory milestone payments as well as royalties on net sales of licensed products to Invivis.
Arno will also receive certain clinical development support services from Invivis pursuant to a separate agreement.
Arno president and CEO Glenn Mattes said Onapristone appears to have a unique ability to block the activated bio-marker and tumor growth.
"We have prepared a detailed development program for this compound and look forward to evaluating it in future clinical trials," Mattes added.